Louvain-La-Neuve, Belgium, September 25, 2017 - IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, is today hosting an event for analysts and investors in the Omni San Diego Hotel during the American Society of Radiation Oncology’s (ASTRO) 59th Annual meeting.
The event will be hosted by Olivier Legrain, Chief Executive Officer, who will provide an overview of IBA’s business as well as discuss its new collaboration with Elekta. No new material information will be provided.
Presentations will also be provided by proton therapy market experts, Dr Andrew K. Lee, Medical Director at the Texas Center for Proton Therapy, Dr Craig Stevens, Chair of Radiation Oncology at the Beaumont Health System and Beth Klein, Executive Vice President at IBA North America.
Ad Statistics
Times Displayed: 49670
Times Visited: 1409 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
The event will be recorded and the recording as well as the presentation will be available on IBA’s website after the event at: https://iba-worldwide.com/content/iba-capital-market-day-astro-annual-meeting-2017
Schedule:
Introduction
Olivier Legrain, Chief Executive Officer, IBA
The role on proton therapy in oncology
Andrew K. Lee, MD, MPH, Medical Director, Texas Center for Proton Therapy
Testimony on the development of a state-of-the-art proton therapy center
Craig W. Stevens, MD, PhD, Chair of Radiation Oncology, Beaumont Health System
North America PT market dynamics
Beth Klein, Executive Vice President at IBA North America.
Question and answer session with all speakers
Optional tour of IBA’s booth, # 2135, from 4pm
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
